Pharmaceutical Research

, Volume 15, Issue 4, pp 599–605 | Cite as

Effect of GF120918, a Potent P-glycoprotein Inhibitor, on Morphine Pharmacokinetics and Pharmacodynamics in the Rat

  • Stephen P. Letrent
  • Gary M. Pollack
  • Kenneth R. Brouwer
  • Kim L. R. Brouwer


Purpose. The objective of this study was to evaluate the effect of a potent P-gp inhibitor, GF120918, on the systemic pharmacokinetics and antinociceptive pharmacodynamics of a single intravenous dose of morphine in rats.

Methods. Male Sprague-Dawley rats received either 500 mg base/kg/d GF120918 or vehicle for 4 days by gavage, or no pretreatment. On day 4, morphine was administered as a 1- or 2-mg/kg i.v. bolus. Antinociception, expressed as percent of maximum possible response (%MPR), was evaluated over 300 min after morphine administration. Serial blood samples were collected and analyzed for morphine and morphine-3-glucuronide (M3G) by HPLC.

Results. Morphine clearance and distribution volume were not altered significantly by GF120918. M3G AUC in the GF120918-treated rats was approximately 2-fold higher than in vehicle-treated rats. For both morphine doses, %MPR and the area under the effect-time curve at 300 min were significantly higher in the GF120918-treated rats. A pharmacokinetic/pharmacodynamic effect model accurately described the effect-concentration data for the rats that received 1-mg/kg morphine; ke0 was significantly smaller for GF 120918- vs. vehicle-treated and control rats (0.060 ± 0.028 vs. 0.228 ± 0.101 vs. 0.274 ± 0.026 min−1, p=0.0023). EC50 and γ were similar between treatment groups.

Conclusions. Pretreatment with GF 120918 enhanced morphine antinociception, as assessed by the hot-lamp tail-flick assay, and elevated systemic M3G concentrations in rats. The differential pharmacologic response to morphine in the GF120918-treated animals could not be attributed to alterations in systemic morphine pharmacokinetics.

morphine morphine-3-glucuronide P-glycoprotein pharmacokinetics pharmacodynamics antinociception central nervous system analgesia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C. Cordon-Cardo, J. P. O'Brien, J. Boccia, D. Casals, J. R. Bertino, and M. R. Melamed. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1277–1287 (1990).Google Scholar
  2. 2.
    F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735–7738 (1987).Google Scholar
  3. 3.
    I. Pastan and M. M. Gottesman. Multidrug resistance. Annu Rev. Med. 42:277–286 (1991).Google Scholar
  4. 4.
    H. L. Pearce, A. R. Safa, N. J. Bach, M. A. Winter, M. C. Cirtain, and W. T. Beck. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. USA 86:5128–5132 (1989).Google Scholar
  5. 5.
    J. M. Zamora, H. L. Pearce, and W. T. Beck. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:454–462 (1988).Google Scholar
  6. 6.
    J. J. Kaufman, N. M. Semo, and W. S. Koski. Microelectrometric titration measurement of the pK's and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence. J. Med. Chem. 18:647–655 (1975).Google Scholar
  7. 7.
    R. Callaghan and J. R. Riordan. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 268:16059–16064 (1993).Google Scholar
  8. 8.
    A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. A. M. Mol, and P. Borst. Absence of the mdr la P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698–1705 (1995).Google Scholar
  9. 9.
    L. J. Goldstein, I. Pastan, and M. M. Gottesman. Multidrug resistance in human cancer. Crit. Rev. Oncol. Hematol. 12:243–253 (1992).Google Scholar
  10. 10.
    F. Hyafil, C. Vergely, P. Du Vignaud, and T. Grand-Perret. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595–4602 (1993).Google Scholar
  11. 11.
    S. M. Witherspoon, D. L. Emerson, B. M. Kerr, T. L. Lloyd, W. S. Dalton, and P. S. Wissel. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin. Cancer Res. 2:7–12 (1996).Google Scholar
  12. 12.
    P. A. Glare, T. D. Walsh, and C. E. Pippenger. A simple method for the simultaneous determination of morphine and its principal metabolites in plasma using high-performance liquid chromatography and fluorometric detection. Ther. Drug Monit. 13:226–232 (1991).Google Scholar
  13. 13.
    R. F. Venn and A. Michalkiewcz. Fast reliable assay for morphine and its metabolites using high-performance liquid chromatography and native fluoresence detection. J. Chromatogr. 525:379–388 (1990).Google Scholar
  14. 14.
    D. M. Ouellet and G. M. Pollack. Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. Drug Metab. Dispos. 23:478–484 (1995).Google Scholar
  15. 15.
    M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd edition, Marcel Dekker, New York, 1982.Google Scholar
  16. 16.
    L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: applications to d-tubocuranine. Clin. Pharmacol. Ther. 25:358–371 (1979).Google Scholar
  17. 17.
    J. H. Jaffe and W. R. Martin. Opioid analgesics and antagonists. In A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, Pergamon Press, New York, 1990, pp. 485–521.Google Scholar
  18. 18.
    A. Sakata, I. Tamai, K. Kawazu, Y. Deguchi, T. Ohnishi, A Saheki, and A Tsuji. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 48:1989–1992 (1994).Google Scholar
  19. 19.
    A. Tsuji, T. Tersaki, Y. Takabatake, Y. Tenda, I. Tamai, T. Yamashima, S. Moritani, T. Tsuruo, and J. Yamashita. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51:1427–1437 (1992).Google Scholar
  20. 20.
    E. G. Chikhale, P. S. Burton, and R. T. Borchardt. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J. Pharmacol. Exp. Ther. 273:298–303 (1995).Google Scholar
  21. 21.
    T. Tatsuta, M. Naito, T. Oh-hara, I. Sugawara, and T. Tsuruo. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267:20383–20391–223 (1992).Google Scholar
  22. 22.
    R. W. Milne, R. L. Nation, and A. A. Somogyi. The disposition of morphine and its 3-and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev. 28:345–472 (1996).Google Scholar
  23. 23.
    T. L. Horton and G. M. Pollack. Enterohepatic recirculation and metabolism of morphine in the rat. J. Pharm. Sci. 80:1147–1152 (1991).Google Scholar
  24. 24.
    M. Gosland, C. Tsuboi, T. Hoffman, S. Goodin, and M. Vore. 17 β-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter. Cancer Res. 53:5382–5385 (1993).Google Scholar
  25. 25.
    Y. Liu, L. Huang, T. Hoffman, M. Gosland, and M. Vore. MDRI substrates/modulators protect against β-estradiol-17β-D-glucuronide cholestasis in rat liver. Cancer Res. 56:4992–4997 (1996).Google Scholar
  26. 26.
    J. Huwyler, J. Drewe, C. Klusemann, and G. Fricker. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br. J. Pharmacol. 118:1879–1885 (1996).Google Scholar
  27. 27.
    K. Hewett, A. H. Dickenson, and H. J. McQuay. Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 53:59–63 (1993).Google Scholar
  28. 28.
    D. M. Ouellet and G. M. Pollack. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. Biochem. Pharmacol. 53:1451–1457 (1997).Google Scholar
  29. 29.
    N. Suzuki, E. Kalso E., and P. H. Rosenberg. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur. J. Pharmacol. 249:247–250 (1993).Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Stephen P. Letrent
    • 1
  • Gary M. Pollack
    • 1
  • Kenneth R. Brouwer
    • 2
  • Kim L. R. Brouwer
    • 1
  1. 1.School of Pharmacy, Division of PharmaceuticsUniversity of North Carolina at Chapel HillChapel Hill
  2. 2.Division of Bioanalysis and Drug MetabolismGlaxo Wellcome Inc

Personalised recommendations